Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Global Growth USA Immuno-Oncology 2017-18

Reference number
Funding from Vinnova SEK 58 892
Project duration November 2017 - April 2018
Status Completed

Purpose and goal

The IO mission to US is expected to provide Immunovia with several new pharma partnership collaborations and hence the development of new innovative predictive (CDx) test solutions/products within IO. During the mission - we will initiate (and later follow-up) on partnering discussions with global pharma executives and identify suitable R&D partners and Clinical Development Centers for novel collaborations.

Expected results and effects

The project (i.e. the mission to US east coast) allowed Immunovia to meet several different companies and different investigators of relevance to Immunovia´s business development. On the company (pharma) side - 5 of the face-to-face meetings held during the US stay have led to follow-up activities/interactions between Immunovia and pharma. On the investigator ( NIH/NCI/Dana Farber etc.) side we experienced several relevant discussions with researchers/tech trans manegers/consultants with regard to the Immunovia technology platform (IMMrayTM).

Planned approach and implementation

Immunovia and two pharma companies/investigators are now discussing concrete project activities, where Immunovia will use it´s IMMrayTM platform to provide services to pharma in regard to patient sample differentiation.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2017-05270

Page statistics